Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: protein serine threonine kinase inhibitors - Myrexis

Next Previous
Search
Drug Profile

Research programme: protein serine threonine kinase inhibitors - Myrexis

Alternative Names: MPI-0485520; MPI-485520

Latest Information Update: 26 Nov 2012

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Myriad Pharmaceuticals
  • Developer Myrexis
  • Class Small molecules
  • Mechanism of Action I-kappa B kinase inhibitors; Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Cancer; Inflammation; Rheumatoid arthritis

Highest Development Phases

  • Suspended Cancer; Diabetes mellitus; Inflammation; Obesity; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 09 Nov 2012 The Board of Directors of Myrexis announces a plan of complete liquidation and dissolution of the company
  • 11 May 2012 MPI 485520 is available for licensing (www.myrexis.com)
  • 26 May 2011 Preclinical trials in Rheumatoid arthritis in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top